13 December 2023
Linklaters advises Novo Holdings and co-advises Novozymes on the European Commission’s Phase I conditional approval of its proposed merger with Chr. Hansen
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nicole Kar Lead | Linklaters | Partner | Antitrust & Foreign Investment | Not stated |
| Antonia Sherman | Linklaters | Partner | Not stated | Washington |
| Xi Liao | Linklaters | Partner | Not stated | Shanghai |
| Zhao Sheng | Linklaters | Not stated | Not stated | Not stated |
| Mark Daniel | Linklaters | Counsel | Not stated | London |
| Emily Burke | Linklaters | Associate | Not stated | London |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Novo Holdings
- Counterparties
- Novozymes A/S (Sell-side)
Christian Hansen A/S (Target)